Immutep Ltd (IMMP) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Quarterly Activities Report Q2 FY25

Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in...

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients...

Patient Enrolment Completed for INSIGHT-003

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with...

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to...

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Media Release SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results...

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Media Release Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the...

Immutep Quarterly Activities Report Q1 FY25

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell...

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

Media Release SYDNEY, AUSTRALIA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...